Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Penguin Solutions Stock Deep Dive: The AI Factory Platform Company Behind Memory, HPC and Full-Stack Infrastructure
Penguin Solutions has moved from the old SMART Global Holdings identity into a more focused AI infrastructure story. The market is no longer looking at PENG as a simple memory-cycle name. It is looking at a company trying to sit at the intersection of accelerated compute, advanced memory, AI cluster software, deployment services and enterprise-scale AI factory buildouts.
Biotech Radar — July 8, 2026: Vertex’s $10B Crinetics Deal, Seres’ Microbiome Signal and OKYO’s FDA Phase 3 Pathway ($CRNX, $MCRB, $OKYO)
Biotech radar: Vertex to acquire Crinetics ($CRNX) for ~$10B, Seres ($MCRB) posts an early 80% Day 15 SER-155 signal in checkpoint-inhibitor enterocolitis, and OKYO ($OKYO) moves urcosimod to Phase 3 NEPTUNE after FDA Type D feedback.
Oil Shock and the Hormuz Premium: Why $CVX, $XOM and $OXY Are Back in Focus
Oil surged over 6% and energy stocks jumped after the U.S.-Iran framework broke down and Iranian oil sanctions returned. The Strait of Hormuz premium puts Chevron ($CVX), Exxon Mobil ($XOM) and Occidental ($OXY) back in focus.
$MSOS $TLRY $CGC $ACB: Cannabis Rescheduling Hearing Update After DEA Recess Order Shifts the July 9 Schedule
The July cannabis trade is no longer about a simple “rescheduling soon” headline. It is about the administrative record being built inside the DEA hearing room: medical use, abuse potential, dependence profile, public-safety arguments, product-standardization attacks, impaired-driving concerns and the litigation path that may follow any final Schedule III decision.
Biotech Radar: $VANI, $PHVS, $TOVX — Three Catalyst Stories From GLP-1 Implants to HAE and Pancreatic Cancer
Today’s radar is not built around one single theme. It is built around three very different biotech catalyst profiles: a small-cap GLP-1 implant narrative, a cleaner late-stage rare-disease regulatory story, and a highly speculative oncology microcap with a real but very early dosing question.
Trump Media & Technology Group ($DJT) Deep Dive: Truth Social, Crypto Treasury, Truth.Fi and the TAE Fusion Merger
Deep dive on Trump Media ($DJT) after Q1 2026: $871K revenue, -$405.9M net loss driven by crypto marks, 9,542 BTC treasury, the CEO change, the paused Truth Social spin-off and the pending ~$6B TAE Technologies fusion merger.
$WULF, $AVGO, $MU: AI Infrastructure Back in Focus as Data Centers Replace the Old Crypto-Mining Story
Deep dive on the July 2026 AI infrastructure trade: TeraWulf's $19B Anthropic data-center lease, Broadcom's Apple custom-chip extension through 2031, and Micron's AI-driven memory super-cycle. $WULF, $AVGO, $MU.
Biotech Radar — July 6, 2026: $PHVS, $AGEN, $IONS (FDA NDA Acceptance, MSS Colorectal Survival Data, Phase 3 Angelman Milestone)
Biotech radar for July 6, 2026: Pharvaris ($PHVS) FDA NDA acceptance with an April 2027 PDUFA date, Agenus ($AGEN) three-year BOT+BAL survival data in MSS colorectal cancer, and Ionis ($IONS) Phase 3 pivotal enrollment complete in Angelman syndrome.
Biotech & Trading Glossary: PDUFA, FDA & Small Caps
70+ biotech, small-cap, FDA and trading terms explained clearly: PDUFA date, CRL, cash runway, short squeeze, surrogate endpoint and more.
Cannabis Rescheduling Watch: Why the Anti-Schedule III Case Matters Before the DEA’s July 15 Deadline
The cannabis trade is not waiting for a simple headline. It is watching an administrative record being built in real time. The key question is not only whether marijuana can move from Schedule I to Schedule III, but whether the evidence supporting that move is strong enough to survive opposition, procedural scrutiny and possible litigation.
AI: the 10 hottest stocks of July 2026
Ten artificial-intelligence names, screened for momentum, chart position and base, with the genuine small/mid caps up top. For each one: a mini chart, a short explainer, the AI niche and the real analyst price targets with sources.
Defense: the 10 hottest stocks of July 2026
Watchlist 2026 · Defense & Defense-Tech Drones Space Counter-UAS Momentum AVAV · KTOS · RKLB · LUNR · PL · DRS · KRMN · RCAT · UMAC · ONDS Defense: the 10 hottest stocks of July 2026 Ten small and…
Atlas Lithium ($ATLX) Deep Dive 2026
The junior developer aiming to bring the Neves hard-rock lithium project into production in Minas Gerais' "Lithium Valley": a fully paid processing plant already shipped to Brazil, offtake deals with Mitsui, Chengxin and Yahua — but also years of delays, heavy dilution and a CEO who controls 51% of the vote.
NANO Nuclear Energy ($NNE) Deep Dive 2026
The microreactor developer aiming to become a fully integrated nuclear supply chain for the AI data-center era: pre-commercial technology, a large cash pile and a calendar of regulatory and test milestones.
$MVIS MicroVision: Small-Cap LiDAR Reawakens as Defense, Security and AI Robotics Become the New Battleground
MicroVision’s new Southeast Asia partnership adds another piece to a busy 2026 commercial reset, but the story remains a high-risk execution trade: stronger customer activity, broader LiDAR portfolio, still-small revenue, meaningful cash burn and visible financing risk.
Biotech Radar July 1, 2026: $CANF, $ABVX, $SXTP and $MODD Lead Today’s Catalyst Watch
Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use.
DEA Cannabis Hearing Begins: Why Schedule III Still Matters for $TLRY, $CGC and $MSOS
The market did not get a final ruling today. What it got is the start of a federal process that could decide whether the cannabis trade remains a narrow medical-only tax story or becomes a broader sector repricing catalyst.
Analyst Price Targets in Biotech: Why the Most Quoted Number Is Often the Least Useful One
A deeper, U.S.-focused Merlintrader editorial on how to read sell-side price targets in small and mid-cap biotech, why 12-month targets often fail as forecasts, and why binary events such as PDUFA dates, Phase 3 readouts and FDA advisory committees can turn the “average target” into a misleading comfort number.
Three Space Stories That Matter Now: $RKLB’s Iridium Shock, $ASTS’s August Launch Window, and Rocket Lab’s NASA Credibility Trade. $IRDM
The public space sector just received a concentrated set of catalysts: Rocket Lab is trying to buy an operating satellite communications network, AST SpaceMobile has placed its next BlueBird batch on the launch calendar, and NASA has selected Rocket Lab for dedicated Sun/Earth science missions. Together, these updates show how the investable space trade is moving beyond launch hype and into infrastructure, networks, services, and execution.
Biotech Radar — June 29, 2026: Ipsen-Kartos M&A, $CAPR’s FDA AdCom and $REPL’s RP1 Resubmission
The biotech calendar is entering a dense FDA-driven window, with three Nasdaq-listed names standing out for very different reasons: a renal-disease PDUFA decision watch, a rare-disease cell therapy advisory committee, and an oncology BLA resubmission that has put accelerated approval back in focus.
